{"id":"W2108851969","doi":"10.1016/j.jalz.2011.05.1371","title":"P2‐499: Safety and efficacy results of a phase II randomized, placebo‐controlled, dose‐ranging study of elnd005 (scyllo‐inositol) in mild‐to‐moderate Alzheimer's disease","year":2011,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Interface Biologics (Canada); University Health Network","funders":"","keywords":"Placebo; Medicine; Discontinuation; Clinical endpoint; Adverse effect; Internal medicine; Randomized controlled trial; Incidence (geometry); Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001422969,0.001253174,0.001630755,0.0004024373,0.0003495234,0.0007358309,0.0008076145,0.001455917,0.005126336],"category_scores_gemma":[0.001187012,0.0004963999,0.001072584,0.0002806433,0.0009655806,0.0006902277,0.0002853239,0.001775991,0.0008254962],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000540753,"about_ca_system_score_gemma":0.0007707928,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006352823,"about_ca_topic_score_gemma":0.001679002,"domain_scores_codex":[0.9994366,0.0002872701,0.00003882836,0.00009089598,0.00006460438,0.00008179277],"domain_scores_gemma":[0.9993927,0.0001859853,0.0001150134,0.00005569835,0.00004169916,0.0002088478],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9430684,0.01870316,0.000922744,0.0003725573,0.0006477291,0.0000725058,0.00004920053,0.0002966756,0.01498427,0.00008578172,0.0007364054,0.02006046],"study_design_scores_gemma":[0.8417762,0.1497702,0.005239705,0.00002003111,0.0004198805,0.00005418689,0.00002275062,0.0004309505,0.001483546,0.00009662088,0.0006648878,0.00002116748],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937978,0.001285094,0.0005758858,0.0002508195,0.0001144245,0.001778734,0.0009191415,0.0001025959,0.001175417],"genre_scores_gemma":[0.9917341,0.001180862,0.00103194,0.0006638364,0.0001801538,0.001747134,0.001391702,0.00002515381,0.002045208],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005126336,"threshold_uncertainty_score":0.01714927,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0389154970870878,"score_gpt":0.3255631500595888,"score_spread":0.286647652972501,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}